Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.17, $0.08 better than the analyst estimate of $1.09. Revenue for the quarter came in at $83.5 million versus the consensus estimate of $80.84 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.

Earnings